Floatz logo

Biperiden

Post Traumatic Epilepsy

Hospital Sirio-LibanesSmall moleculePhase 3Active
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Post Traumatic Epilepsy cohort.

Asset / SponsorPhaseRating
Valproic Acid
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 3B
PHENYTOIN
Cambridge University Hospitals NHS Foundation Trust
Phase 3B
PHENYTOIN
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 3B
ALLOPREGNAN-3.ALPHA.-OL-20-ONE
Michael A. Rogawski, MD, PhD
Phase 2B
Po Brc-003
Dr. Paul Lyons
Phase 2NR

Same molecule, other indications

Biperiden is also rated in:

dementiaDormant
CC
Indicative ·
40 / 100
View asset →
depressive disorderDormant
CC
Indicative ·
40 / 100
View asset →
traumatic brain injuryDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →